Salvage Treatment and the Role of Transplantation in Lymphomas

Czech version

Authors: D. Pohlreich; B. Vacková; R. Pytlík; M. Trnková; M. Trněný
Authors‘ workplace: I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze
Published in: Klin Onkol 2015; 28(Supplementum 3): 95-104
doi: https://doi.org/10.14735/amko20153S95

Overview

Despite achieving promising treatment results in patients with lymphoma, there is still a significant proportion of patients who relapse or have refractory disease. Salvage therapy followed by high dose treatment with autologous stem‑ cell transplantation is the standard of care in many of them. The role allogeneic stem‑ cell transplantation, especially after reduced intensity conditioning, is under extensive investigation. This review article presents current knowledge and recommendation in the salvage treatment of relapsed/ refractory lymphomas.

Key words:
refractory/ relapsed lymphoma – Hodgkin’s lymphoma – diffuse large B‑ cell lymphoma – follicular lymphoma – T-cell non-Hodgkin lymphoma – autologous stem cell transplantation – allogeneic hematopoietic stem cell transplantation

This work was supported by research projects NT12193-5/2011, NT11299-6/2010 and NT13072-4/2012.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
27. 9. 2015

Accepted:
29. 9. 2015

Sources

1. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009; 497– 506. doi: 10.1182/ asheducation‑ 2009.1.497.

2. Schmitz N, Pfistner B, Sextro M et. al. Aggressive conventional chemotherapy compared with high‑dose chemotherapy with autologous haemopoietic stem‑ cell transplantation for relapsed chemosensitive Hodgkin‘s disease: a randomised trial. Lancet 2002; 359(9323): 2065– 2071.

3. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone‑ marrow transplantation in relapsed and resistant Hodgkin‘s disease: results of a BNLI randomised trial. Lancet 1993; 341(8852): 1051– 1054.

4. Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96(4): 1280– 1286.

5. Josting A, Muller H, Brochmann P et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin‘s lymphoma. J Clin Oncol 2010; 28(34): 5074– 5080. doi: 10.1200/ JCO.2010.30.5771.

6. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011; 117(16): 4208– 4217. doi: 10.1182/ blood‑ 2010‑ 09‑ 288373.

7. Jabbour E. Hosing C, Ayers G et al. Pretransplant positive positron emission tomography/ gallium scans predict poor outcome in patients with recurrent/ refractory Hodgkin lymphoma. Cancer 2007; 109(12): 2481– 2489.

8. Moskowitz AJ, Yahalom J, Kewalramani T et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116(23): 4934– 4947. doi: 10.1182/ blood‑ 2010‑ 05‑ 282756.

9. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin‘s disease. J Clin Oncol 1991; 9(10): 1871– 1879.

10. Visani G, MalerbaL, Stefani PM et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/ relapsed lymphoma patients. Blood 2001; 118(12): 3419– 3425. doi: 10.1182/ blood‑ 2011‑ 04‑ 351924.

11. Fung HC, Stiff P, Schriber J et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marr Transplant 2007: 13(5): 594– 600.

12. Morschhauser F, Brice P, Fermé C et al. Risk‑adapted salvage treatment with single or tandem autologous stem‑ cell transplantation for first relapse/ refractory Hodgkin‘s lymphoma: results of the prospective multicenter H96 trial by the GELA/ SFGM study group. J Clin Oncol 2008; 26(36): 5980– 5897. doi: 10.1200/ JCO.2007.15.5887.

13. Devillier R, Coso D, Castagna L et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/ or refractory Hodgkin‘s lymphoma responding to prior salvage therapy. Haematologica 2012; 97(7): 1073– 1079. doi: 10.3324/ haematol.2011.056051.

14. Pohlreich D, Vackova B, Trnkova M et al. Fifty percent cure rate in poor risk relapsed/ refractory Hodgkin lymphoma after tandem autologous stem cell transplantation. EBMT 2014: abstr. 2381.

15. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA‑identical siblings in advanced Hodgkin‘s disease. J Clin Oncol 1996: 14(2): 572– 578.

16. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin‘s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996: 14(4): 1291– 1296.

17. Sureda A, Robinson S, Canals C et al. Reduced‑ intensity conditioning compared with conventional allogeneic stem‑ cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lamphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008: 26(3): 455– 462.

18. Robinson SP, Sureda A, Canals C et al. Reduced intensity allogeneic stem cell transplantation for hodgkin’s lymphoma: Identification of prognostic factors predicting outcome. Haematol 2009; 94(2): 230– 238. doi: 10.3324/ haematol.13441.

19. Burroughs LM, O’Donnel PV, Sandmaier BM et al. Comparison of outcomes of HLA‑matched related, unrelated, or HLA‑haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplantation 2008; 14(11): 1279– 1287. doi: 10.1016/ j.bbmt.2008.08.014.

20. Peggs KS, Kasvani I, Edwards N et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T‑ cell‑ depleted allogeneic transplantation for Hodgkin’s lymfoma. J Clin Oncol 2011: 29(8): 971– 978. doi: 10.1200/ JCO.2010.32.1711.

21. Coiffier B, Lepage E, Briere J et al. CHOP like chemotherapy plus rituximabcompared with CHOP alone inelderly patients with diffuse large‑ B‑ cell lymphoma. N Engl J Med 2002; 346(4): 235– 242.

22. Pfreundschuh M, Trümper L, Ostergorg A et al. CHOP‑like chemotherapy plus rituximab versus CHOP‑like chemotherapy alone inyoung patients with good‑ prognosis diffuse large‑ B‑ cell lymphoma: a randomized controlled trial by the MabThera International Trial Group. Lancet Oncol 2006; 7(5): 379– 391.

23. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy‑ sensitive non‑Hodkin’s lymphoma. N Eng J Med 1995; 333(23): 1540– 1545.

24. Thieblemont C, Briere J, Mounier N et al. The germinal center/ activated B‑ cell subclassification has a prognostic impact for response to salvage therapy in relapsed/ refractory diffuse large B‑ cell lymphoma: a bio‑ CORAL study. J Clin Oncol 2011; 29(31): 4079– 4087. doi: 10.1200/ JCO.2011.35.4423.

25. Gisselbrecht C, Glass B, Mounier N et al. Salvage regiments with autologous transplantation for relapsed large B‑ cell lymphomain the rituximab era. J Clin Oncol 2010; 28(27): 4184– 4190. doi: 10.1200/ JCO.2010.28.1618.

26. Crump M, Kuruvilla J, Couban S et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem‑ cell transplantation for relapsed and refractory aggressive lymphomas: NCIC‑ CTG LY.12. J Clin Oncol 2014: 32(31): 3490– 3496. doi: 10.1200/ JCO.2013.53.9593.

27. Martín A, Conde E, Arnan M et al. R‑ ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B‑ cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/ TAMO study. Haematologica 2008; 93(12): 1829– 1836. doi: 10.3324/ haematol.13440.

28. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second‑line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B‑ cell lymphoma. Ann Hematol 2007; 86: 107– 115.

29. Vellenga E, van Putten WT, van’t Veer MB et al. Rituximab improves the treatment results of DHAP‑ VIM‑ DHAP and ASCTin relapsed/ progressive agressive CD 20+ NHL: a prospective randomised HOVON trial. Blood 2008; 111(2): 537– 543.

30. Van Kampen RJ, Canals C, Schouten HC et al. Allogeneic stem‑ cell transplantation as salvage therapy for patients with diffuse large B‑ cell lymphoma Relapsing after an autologous stem‑ cell transplantation: an analysis of the Euuropean Group for Blood and Marrow Transplantation registry. J Clin Oncol 2011; 29(10): 1342– 1348. doi: 10.1200/ JCO.2010.30.2596.

31. Freytes CO, Zhang MJ, Carreras J et al. Outcome of lower‑ intensity allogeneic transplantation in non‑Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant 2012; 18(8): 1255– 1264. doi: 10.1016/ j.bbmt.2011.12.581.

32. Sureda A, Bader P, Cesaro S et al. Indications for allo‑ and auto‑ SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marr Transpl 2015: 50(8): 1037– 1056. doi: 10.1038/ bmt.2015.6.

33. Al Khabori, de Almeida JR, Guyatt GH et al. Autologous stem cell transplantation in follicular lymphoma: A systematic review and meta‑analysis. J Natl Cancer Inst 2012; 104(1): 18– 28. doi: 10.1093/ jnci/ djr450.

34. Schouten HC, Qian W, Kvaloy S et al. High‑dose therapy improves progression‑free survival and survival in relapsed follicular non‑Hodgkin‘s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21(21): 3918– 3927.

35. Sebban C, Brice P, Delarue R et al. Impact of rituximab and/ or high‑dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26(21): 3614– 3620. doi: 10.1200/ JCO.2007.15.5358.

36. Kornacker M, Stumm J, Pott C et al. Characteristics of relapse after autologous stem‑ cell transplantation for follicular lymphoma: a long‑term follow‑up. Ann Oncol 2009; 20(4): 722– 728. doi: 10.1093/ annonc/ mdn691.

37. Pettengell R, Schmitz N, Gisselbrecht C et al. Rituximab purging and/ or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2013; 31(13): 1624– 1630. doi: 10.1200/ JCO.2012.47.1862.

38. Vose J, Armitage J, Weisenburger D et al. International peripheral T‑ cell and natural killer/ T‑ cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26(25): 4124– 4130. doi: 10.1200/ JCO.2008.16.4558.

39. Schmitz N, Trümper L, Ziepert M et al. Treatment and prognosis of mature T‑ cell and NK‑ cell lymphoma: an analysis of patients with T‑ cell lymphoma treated in studies of the German High‑Grade Non‑ Hodgkin Lymphoma Study Group. Blood 2010; 116(18): 3418– 3425. doi: 10.1182/ blood‑ 2010‑ 02‑ 270785.

40. Janikova A, Bortlicek Z, et al. CHOEP versus CHOP gives better results in first‑line therapy of t‑ cell lymphoma. A retrospective analysis from czech lymphoma study group (CLSG) database. Hematological Oncology 2015; 33 (Suppl 1): abstr. 99.

41. Corradini P, Tarella C, Zallio F et al. Long‑term follow‑up of patients with peripheral T‑ cell lymphomas treated up‑ front with high dose chemotherapy followed by autologous stem cell transplantaion. Leukemia 2006; 20(9): 1533– 1538.

42. Rodrigues J, Conde E, Gutiérrez A et al. Frontline autologous stem cell transplantation in high‑risk peripheral T‑ cell lymphoma: a prospective study from The Gel‑ Tamo Study Group. Eur J Haematol 2007; 79(1): 32– 38.

43. Reimer P, Rüdiger T, Geissinger E et al. Autologous stem cell transplantation as first‑line therapy in peripheral T‑ cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27(1): 106– 113. doi: 10.1200/ JCO.2008.17.4870.

44. d‘Amore F, Relander T, Lauritzsen GF et al. Up‑ front autologous stem‑ cell transplantation in peripheral T‑ cell lymphoma: NLG‑ T‑ 01. J Clin Oncol 2012; 30(25): 3093– 3099. doi: 10.1200/ JCO.2011.40.2719.

45. Rodrigues J, Caballero MD, Gutiérrez A et al. High‑dose chemotherapy and autologous stem cell transplantation in peripheral T‑ cell lymphoma: the GEL‑ TAMO experience. Ann Oncol 2003; 14(12): 1768– 1775.

46. Rodrigues J, Conde E, Gutiérrez A et al. The adujusted International Prognostic Index and beta‑2– microglobulin predict the outcome after autologous stem cell transplantation in relapsing/ refraktory peripheral T‑ cell lymphoma. Haematologica 2007; 92(8): 1067– 1074.

47. Chen A, McMillan A, Negrin RS et al. Long‑term results af autologous hematopoietic cell transplantation for peripheral T‑ cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008; 14(7): 741– 747. doi: 10.1016/ j.bbmt.2008.04.004.

48. Kyriakou C, Canals C, Goldstone A et al. High‑dose therapy and autologous stem‑ cell transplantation in angioimunoblaststic lymphoma: complete remission at transplantation is the major determinant of outcome – Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26(2): 218– 224. doi: 10.1200/ JCO.2007.12.6219.

49. Dodero A, Spina F, Narni F et al. Allogeneic transplantation following a reduced intensity conditioning regimen in relapsed/ refractory peripheral T‑ cell lymphomas: long term remissions and response to donor lymphocyte infusions support the role of a graft versus lymphoma effect. Leukemia 2012; 26(3): 520– 526. doi: 10.1038/ leu.2011.240.

50. Valkova V, Benesova K, Vitek A et al. The results of allogeneic transplants in patients with malignant lymphoma‑ a retrospective analysis of data from the Czech National Registry. Neoplasma 2009; 56(1): 76– 83.

51. Corradini P, Vitolo U, Rambaldi A et al. Intensified chemo‑ immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T‑ cell lymphoma. Leukemia 2014; 28(9): 1885– 1891. doi: 10.1038/ leu.2014.79.

52. Schmitz N, Nickelsen M, Altmann B et al. Allogeneic or autologous transplantation as first‑line therapy for younger patients with peripheral T‑ cell lymphoma: results of the interim analysis of the AATT trial. J Clin Oncol ASCO Meeting Abstracts 2015; 33 (15 Suppl): 8507.